Cellectar consultant granted 15,000 stock options

Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options.

Rhea-AI Filing Summary

Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options. The award covers 15,000 stock options with an exercise price of $2.6800 per share, expiring on July 8, 2036. These options relate to 15,000 shares of common stock and will vest in full on July 8, 2027, subject to continued service. Following this grant, Stefan holds 15,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Loren Stefan

Role Insider

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 15,000 options Exercise price: $2.6800 per share Underlying shares: 15,000 shares +2 more

5 metrics

Options granted 15,000 options Stock option grant to consultant Loren Stefan

Exercise price $2.6800 per share Strike price for granted stock options

Underlying shares 15,000 shares Common stock underlying the options

Expiration date July 8, 2036 Option expiration for this grant

Post-transaction derivative holdings 15,000 options Total derivative securities held after grant

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, exercise price, vesting

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 2.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option shall vest in full on July 8, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cellectar Biosciences (CLRB) report for Loren Stefan?

Cellectar Biosciences reported that consultant Loren Stefan received a grant of 15,000 stock options. The options give the right to buy common shares at a set price and represent compensation rather than an open-market share purchase or sale.

How many Cellectar Biosciences (CLRB) options were granted to Loren Stefan and at what price?

Loren Stefan was granted 15,000 stock options with an exercise price of $2.6800 per share. Each option relates to one share of Cellectar common stock, providing potential future equity exposure if exercised at or above the strike price.

When do Loren Stefan’s CLRB stock options vest and when do they expire?

The 15,000 Cellectar stock options granted to Loren Stefan vest in full on July 8, 2027. They carry an expiration date of July 8, 2036, giving a multi-year window after vesting to decide whether to exercise the options.

Is Loren Stefan’s Cellectar (CLRB) option grant a market purchase or sale of shares?

The filing shows a grant of stock options, not a market trade in existing shares. This is compensation classified as a grant, award, or other acquisition, so it does not represent an open-market buy or sell transaction in Cellectar stock.

What is Loren Stefan’s reported Cellectar (CLRB) derivative holdings after this option grant?

After the transaction, Loren Stefan is reported to hold 15,000 derivative securities, all from this option grant. These are held directly and represent rights to acquire common shares at the fixed exercise price if exercised in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loren Stefan

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Consultant

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.68	07/08/2026		A		15,000		(1)	07/08/2036	Common stock	15,000	$0	15,000	D

Explanation of Responses:

1. This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Chad Kolean, attorney-in-fact for Stefan Loren	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)